The pharmaceutical industry is highly competitive and driven by innovation. Those two facts could not be clearer than in the competition between Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the newly created GLP-1 weight loss space. While Eli Lilly looks like the winner right now, Novo Nordisk’s Wegovy pill is working better than…
Sales of Eli Lilly (NYSE: LLY) Mounjaro and Zepbound have been amazing. The two GLP-1 drugs saw sales increases of 99% and 175%, respectively, in 2025. The company is at the forefront of this still-in-development drug niche. It’s no surprise that Eli Lilly stock has risen more than 1,100% in the last decade, comfortably outperforming…
Amazon (AMZN) shares soared on Thursday, boosted by CEO Jassy’s shareholder letter revealing $15 billion in annualized AI revenue from AWS and a $200 billion capital spending commitment by 2026 for AI infrastructure. Amazon’s acquisition talks with Globalstar (GSAT) would strengthen Project Kuiper’s satellite internet against SpaceX’s Starlink, while Amazon Pharmacy’s same-day delivery of Eli…
Examining the Lehigh Valley’s historic industrial sites along the Lehigh River evokes a bygone era when the region was home to one of the largest steel production centers in the world. Today, recent investments point to a new manufacturing renaissance, driven by a strategic shift toward life sciences. The zenith of this change came when…
Bernstein just added new fuel to Eli Lilly’s (LLY) endless rally, as the company raised its stock price target to $1,300 from $1,100. For perspective, this is an 18% increase compared to the previous target, although it represents a 21% to 22% advantage compared to Lilly’s current stock price. Analyst Courtney Breen believes Wall Street…
